Filing search / Prime Medicine, Inc. / "Assessment"

8-K

EX-99.1

PRME Prime Medicine, Inc.

13 Jan 25

1 Delivering on the promise of Prime Editing January 2025 Corporate Presentation

8:01am

Prime Medicine believes the technology is for making the edit, based on Prime Medicine’s internal assessment = capable of the edit +++++ 38*Not part

8-K

EX-99.3

PRME Prime Medicine, Inc.

30 Sep 24

Entry into a Material Definitive Agreement

7:38am

assessment = capable of the edit +++++ Flexibility to select right approach for each indication based on editing need 15 PASSIGE Technology Enables

PRE 14A

1c63jhhr46nnpvh7

19 Apr 24

Preliminary proxy

4:07pm

424B5

tdq1bzqc

16 Feb 24

Prospectus supplement for primary offering

6:17am

424B5

rgr7c

14 Feb 24

Prospectus supplement for primary offering

5:27pm

S-3

sjab22yuyy6v2ip jap

3 Nov 23

Shelf registration

5:23pm

S-3

EX-4.6

ixb2jehdqycit

3 Nov 23

Shelf registration

5:23pm

S-3

EX-4.5

l8c4m6e

3 Nov 23

Shelf registration

5:23pm

DEF 14A

3dj8vo1j lcbsdkv6

28 Apr 23

Definitive proxy

8:34am

10-Q

741hcb9i

14 Nov 22

Quarterly report

4:46pm

424B4

0h0psvl5ba1lnx90e1vw

21 Oct 22

Prospectus supplement with pricing info

4:47pm

S-1/A

vwqi2bvpsfkr0d

13 Oct 22

IPO registration (amended)

10:51am

S-1

EX-10.18

rw3x4s

23 Sep 22

IPO registration

4:12pm